es | en | pt | fr
    • Presentación
    • Países
    • Instituciones
    • Participa
        JavaScript is disabled for your browser. Some features of this site may not work without it.
        Ver ítem 
        •   Inicio
        • Argentina
        • Gobierno
        • Comisión de Investigaciones Científicas (Argentina)
        • Ver ítem
        •   Inicio
        • Argentina
        • Gobierno
        • Comisión de Investigaciones Científicas (Argentina)
        • Ver ítem

        Erythropoietin Treatment in Chronic Renal Failure Anaemia-Biosimilar Option in the Rational Use of Medicine Process in Order to Reduced Public Health Economic Burden

        Registro en:
        http://digital.cic.gba.gob.ar/handle/11746/8924
        http://repositorioslatinoamericanos.uchile.cl/handle/2250/2858008
        Autor
        Marín, Gustavo H.
        Marín, Lupe
        Haag, Griselda
        Risso, Paula
        Errecalde, Jorge
        Institución
        • Comisión de Investigaciones Científicas (Argentina)
        Resumen
        Biopharmaceuticals innovation molecules have changed the course of a large number of chronic diseases. Many of these molecules became Gold Standards in oncology, rheumatology and other illness. However, their cost makes these drugs unattainable for most patients, and often put the health systems' budgets at risk. This study takes the anaemia due to Chronic Renal Failure disease (CRFD) as an example to a rational selection of treatment with erythropoietin (EPO) and compares the trade brand mark of this drug with biosimilars option. Prescriptions of EPO in 394 patients with CRFD were submitted to a protocol of rational selection based in efficacy/risk ratio demonstration. This protocol was able to reduce that initial number to 91 cases that could really benefited with EPO treatment. These patients were included in a cohort study that compared EPO trade mark with biosimilars option. The experience demonstrated equal clinical outcomes in both groups but a reduction to half the original cost when biosimilars were dispensed. Biosimilars demonstrated to be a cheap and safe option to increase medicine access for anaemia associated to CRFD.
        Materias
        Ciencias de la Salud

        Mostrar el registro completo del ítem


        Red de Repositorios Latinoamericanos
        + de 8.000.000 publicaciones disponibles
        500 instituciones participantes
        Dirección de Servicios de Información y Bibliotecas (SISIB)
        Universidad de Chile
        Ingreso Administradores
        Colecciones destacadas
        • Tesis latinoamericanas
        • Tesis argentinas
        • Tesis chilenas
        • Tesis peruanas
        Nuevas incorporaciones
        • Argentina
        • Brasil
        • Colombia
        • México
        Dirección de Servicios de Información y Bibliotecas (SISIB)
        Universidad de Chile
        Red de Repositorios Latinoamericanos | 2006-2018
         

        EXPLORAR POR

        Instituciones
        Fecha2011 - 20202001 - 20101951 - 20001901 - 19501800 - 1900

        Explorar en Red de Repositorios

        Países >
        Tipo de documento >
        Fecha de publicación >
        Instituciones >

        Red de Repositorios Latinoamericanos
        + de 8.000.000 publicaciones disponibles
        500 instituciones participantes
        Dirección de Servicios de Información y Bibliotecas (SISIB)
        Universidad de Chile
        Ingreso Administradores
        Colecciones destacadas
        • Tesis latinoamericanas
        • Tesis argentinas
        • Tesis chilenas
        • Tesis peruanas
        Nuevas incorporaciones
        • Argentina
        • Brasil
        • Colombia
        • México
        Dirección de Servicios de Información y Bibliotecas (SISIB)
        Universidad de Chile
        Red de Repositorios Latinoamericanos | 2006-2018